Drugs / Teprotumumab N01
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT07594912 | Aug 2026 → Dec 2027 expected | disease of orbital part of eye adnexa, optic nerve disorder | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT07265258 | Dec 2025 → Sep 2026 overdue | endocrine exophthalmos | Innovent Biologics (Suzhou) Co. Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Teprotumumab N01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07594912 ↗ |
| Action | Inhibit | “IGF-1R inhibitor” NCT07594912 ↗ |
| Modality | Monoclonal antibody | “Insulin-like growth factor-1 receptor monoclonal antibody” NCT07594912 ↗ |
| Route | Intravenous | “Participants will be randomized 1:1 to receive either intravenous teprotumumab N01” PMID 42448986 ↗ Jul 2026 |
| Target | IGF1R | “IGF-1R inhibitor” NCT07594912 ↗ |